Your browser doesn't support javascript.
loading
Asymptomatic multicentric Castleman disease: A potential early stage of idiopathic MCD.
Zhang, Lu; Liu, Qin-Hua; Zhou, Hui; Zhang, Hui-Lai; Dong, Yu-Jun; Wang, Xiao-Bo; Wang, Lu-Qun; Su, Li-Ping; Yan, Xiao-Jing; Li, Yan; Zhang, Ming-Zhi; Ding, Kai-Yang; Wang, Hui-Han; Peng, Hong-Ling; Zhong, Li-Ye; Yang, Lin; Bi, Lin-Tao; Gao, Da; Gao, Guang-Xun; Huang, Liang; Sun, Chun-Yan; Song, Jia; Qian, Wenbin; Huang, Wen-Rong; Li, Zhen-Ling; Liu, Yao; Li, Jian.
Afiliación
  • Zhang L; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China.
  • Liu QH; The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Zhou H; Hunan Cancer Hospital, Changsha, China.
  • Zhang HL; Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Dong YJ; Peking University First Hospital, Beijing, China.
  • Wang XB; The Second Hospital of Dalian Medical University, Dalian, China.
  • Wang LQ; Qilu Hospital, Shandong University.
  • Su LP; Department of Hematology, Shanxi Provincial Cancer Hospital, Taiyuan, China.
  • Yan XJ; Department of Hematology, First Hospital of China Medical University, Shenyang, China.
  • Li Y; People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
  • Zhang MZ; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Ding KY; The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, China.
  • Wang HH; Sheng Jing Hospital of China Medical University, Shenyang, China.
  • Peng HL; Department of Hematology, The Second Xiangya Hospital, Central South University, P.R. China, Chang Sha, China.
  • Zhong LY; The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Yang L; Second Hospital of Hebei Medical University, Shijiazhuang, China.
  • Bi LT; Jilin University, Changchun, China.
  • Gao D; The Affiliated Hospital of Inner Mongolia Medical University, Hothot, China.
  • Gao GX; Xijing Hospital, Air Force Medical University, Xi'an, China.
  • Huang L; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Sun CY; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan, China.
  • Song J; Tianjin Medical University General Hospital, Tianjin, China.
  • Qian W; the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Huang WR; Chinese PLA General Hospital, Beijing, China.
  • Li ZL; China-Japan Friendship Hospital, Beijing, China.
  • Liu Y; Department of Hematology, Xinqiao Hospital, Army Medical University.
  • Li J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Blood Adv ; 2024 Sep 18.
Article en En | MEDLINE | ID: mdl-39293084
ABSTRACT
According to the diagnostic criteria for HHV-8 (human herpesvirus-8) negative/idiopathic multicentric Castleman disease (iMCD) proposed by Castleman Disease Collaborative Network (CDCN) in 2017, there is a group of HHV-8 negative multicentric Castleman disease (MCD) patients who do not have symptoms and hyperinflammatory state and do not meet the iMCD criteria. This retrospective study enrolled 114 such patients, described as asymptomatic MCD (aMCD), from 26 Chinese centers from 2000-2021. With a median follow-up time of 46.5 months (range 4-279 months), 6 patients (5.3%) transformed to iMCD. The median time between diagnosis of aMCD and iMCD in these 6 patients was 28.5 months (range 3-60 months). During follow-up, 7 patients died; three of them died from progression of MCD. Despite that 37.7% patients received systemic treatment targeting MCD, this strategy was neither associated with a lower probability of iMCD transformation nor a lower death rate. The 5-year estimated survival of all aMCD patients was 94.1% (95% CI 88.8-99.6%). Transformation to iMCD was an important predictor of death (log-rank p=0.01) (5-year estimated survival 83.3%). This study suggests that aMCD patients may represent a potential early stage of iMCD, who may not require immediate treatment but should be closely monitored.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Blood Adv Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos